The trend of opting for obesity medicines over bariatric surgery is increasing, with a study finding a 25.6% decrease in bariatric surgery rates between 2022 and 2023 as prescriptions for GLP-1 drugs doubled. This shift raises concerns about the future of surgical programs that rely on such procedures for revenue. While some believe that drugs may replace surgery due to their effectiveness and ease of use, others predict an increase in surgical treatments as weight loss drugs gain popularity. The cost-effectiveness and long-term impact of both options remain uncertain, with insurance coverage playing a significant role in patient choice.
Source link
Bariatric surgery rates plunge as patients turn to GLP-1 drugs
